Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GLB-001 in Relapsed or Refractory AML and HR-MDS
NCT06146257Phase 1Recruiting
- Sponsor
- GluBio Therapeutics
- Start
- Jan 2024
- Primary completion
- Jul 2026
- Modality
- Molecular Glues
- Countries
- 1
01
Overview
Phase 1, open-label trial of GLB-001 in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) (2 arms), sponsored by GluBio Therapeutics. Primary endpoints: Dose-limiting Toxicity up to 28 days, Maximum Tolerated Dose / Maximum Administered Dose up to 2 years and 2 more. Started Jan 2024; status: recruiting.
02
Drugs
GLB-001
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT06146257.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06146257.